Global Reach Atlantis Health services pharma and life sciences clients across multiple regions including the United States, United Kingdom, Germany, Australia and New Zealand, indicating opportunity to cross-sell patient engagement solutions to multinational pharma accounts with global patient support needs.

Strong Outcomes Demonstrated program results such as 25% lift in treatment persistence, 88% patient retention in support programs, and a 96% client satisfaction rating. These metrics can be used to articulate value in proposals and to upsell expanded patient engagement programs.

Rare Disease Focus Recent Rare Disease Report launches and a specialization in rare disease nonadherence provide a pathway to target orphan and specialty therapies that require tailored adherence and education programs.

Digital & AI Edge Emphasis on behavioral science, AI and omnichannel technologies supports upsell opportunities around digital strategy, patient journey optimization, and scalable online engagement platforms for diverse therapeutic areas.

Expansive Health Scope Experience across more than 100 health conditions, including cancer, diabetes and asthma, suggests potential for expanding services into broader indications and near-term opportunities with existing clients seeking comprehensive patient support ecosystems.